Dr Donald L. Lamm

Dr Donald L. Lamm's AcademicInfluence.com Rankings

Dr Donald L. Lamm

Philosophy

#7993

World Rank

#11290

Historical Rank

Logic

#5025

World Rank

#6380

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Dr Donald L. Lamm's Degrees

Doctorate Medicine University of Miami

Why Is Dr Donald L. Lamm Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Dr Donald L. Lamm's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. (2002) (1157)
Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. (2000) (1116)
Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. (1992) (694)
A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder. (1991) (541)
Complications of bacillus Calmette-Guerin immunotherapy in 1,278 patients with bladder cancer. (1986) (355)
Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. (1996) (321)
Bacillus Calmette-Guerin immunotherapy for bladder cancer. (1985) (284)
A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group. (2011) (280)
Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer. (1980) (268)
Long-term results of intravesical therapy for superficial bladder cancer. (1992) (267)
Definitions, End Points, and Clinical Trial Designs for Non-Muscle-Invasive Bladder Cancer: Recommendations From the International Bladder Cancer Group. (2016) (257)
Complications of bacillus Calmette-Guérin immunotherapy. (1992) (251)
Efficacy and safety of bacille Calmette-Guérin immunotherapy in superficial bladder cancer. (2000) (248)
Management of stage T1 tumors of the bladder: International Consensus Panel. (2005) (204)
Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder. (1995) (196)
Expert consensus document: Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer (2015) (195)
A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer. (2012) (188)
Improved detection of recurrent bladder cancer using the Bard BTA stat Test. (1998) (184)
Megadose vitamins in bladder cancer: a double-blind clinical trial. (1994) (174)
Photodynamic therapy (PDT) in the treatment of patients with resistant superficial bladder cancer: a long-term experience. (1998) (144)
Phase I/II marker lesion study of intravesical BC-819 DNA plasmid in H19 over expressing superficial bladder cancer refractory to bacillus Calmette-Guerin. (2008) (139)
Urinary nuclear matrix protein as a marker for transitional cell carcinoma of the urinary tract. (1996) (137)
Bacillus Calmette‐Guérin immunotherapy for genitourinary cancer (2013) (134)
Randomized intergroup comparison of bacillus calmette-guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder a southwest oncology group study. (1995) (129)
Epidemiology, Staging, Grading, and Risk Stratification of Bladder Cancer (2008) (128)
Bladder cancer immunotherapy. (1982) (126)
Complications of laparoscopic nephrectomy: the Mayo clinic experience. (2004) (125)
A multicenter trial evaluation of the fibrin/fibrinogen degradation products test for detection and monitoring of bladder cancer. (1997) (123)
An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: Interim results. (2017) (123)
Fatal sepsis following intravesical bacillus Calmette-Guerin administration for bladder cancer. (1990) (121)
Enhanced immunocompetence by garlic: role in bladder cancer and other malignancies. (2001) (115)
Clinical Practice Recommendations for the Prevention and Management of Intravesical Therapy-Associated Adverse Events. (2008) (108)
Superficial bladder cancer (2002) (106)
Effect of autolymphocyte therapy on survival and quality of life in patients with metastatic renal-cell carcinoma (1990) (106)
Complications of Bacillus Calmette-Guerin immunotherapy: review of 2602 patients and comparison of chemotherapy complications. (1989) (105)
Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscleinvasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette- Guérin (BCG): results of an international individual patient data survey (IPDS) (2013) (104)
BCG immunotherapy of bladder cancer: Inhibition of tumor recurrence and associated immune responses (1981) (104)
Bacillus Calmette-Guérin with or without interferon α-2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer. (2010) (102)
Defining progression in nonmuscle invasive bladder cancer: it is time for a new, standard definition. (2014) (100)
BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG (2017) (95)
Long-term results of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer. (1989) (94)
DNA based therapy with diphtheria toxin-A BC-819: a phase 2b marker lesion trial in patients with intermediate risk nonmuscle invasive bladder cancer. (2014) (86)
Defining and treating the spectrum of intermediate risk nonmuscle invasive bladder cancer. (2014) (83)
Immunotherapy of murine transitional cell carcinoma. (1982) (78)
Bladder cancer, 1996 (1996) (76)
Chemoprevention of urological cancer. (1999) (74)
Long-term complete remission in bladder carcinoma in situ with intravesical TICE bacillus Calmette Guerin. Overview analysis of six phase II clinical trials. (1991) (74)
The potential application of Allium sativum (garlic) for the treatment of bladder cancer. (2000) (73)
Prediction of bladder tumor invasion with the mixed cell agglutination test. (1980) (71)
Keyhole Limpet Hemocyanin Immunotherapy of Bladder Cancer: Laboratory and Clinical Studies (2000) (71)
Metallothionein isoform 3 as a potential biomarker for human bladder cancer. (2000) (71)
Allium sativum (garlic) treatment for murine transitional cell carcinoma (1997) (67)
Multi-Institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy of Non-muscle Invasive Bladder Cancer. (2019) (66)
Mayo Clinic Scottsdale experience with laparoscopic nephron sparing surgery for renal tumors. (2003) (66)
Characterization of unoccupied (R) and occupied (RA) androgen binding components of the hyperplastic human prostate (1978) (65)
BCG in perspective: advances in the treatment of superficial bladder cancer. (1995) (64)
Antibiotic and steroid therapy of massive systemic bacillus Calmette-Guerin toxicity. (1992) (63)
Immunotherapy of bladder cancer. (1997) (60)
Bladder cancer: narrowing the gap between evidence and practice. (2009) (58)
Superficial Bladder Cancer Therapy (2004) (56)
BCG immunotherapy for transitional-cell carcinoma in situ of the bladder. (1995) (54)
Antibody responses to Bacillus Calmette-Guérin during immunotherapy in bladder cancer patients. (1981) (51)
Clonogenic assay and in vitro chemosensitivity testing of human urologic malignancies (1982) (51)
Antitumor activity of common antibiotics against superficial bladder cancer. (2004) (51)
Preventing Progression and Improving Survival with BCG Maintenance (1999) (50)
Metallothionein isoform 1 and 2 gene expression in the human bladder: evidence for upregulation of MT-1X mRNA in bladder cancer. (2001) (50)
Updated concepts and treatment of carcinoma in situ. (1998) (49)
Interferon alfa in the treatment paradigm for non-muscle-invasive bladder cancer. (2014) (46)
A trial of bacillus Calmette-Guérin versus adriamycin in superficial bladder cancer: a South-West Oncology Group Study. (1986) (43)
Phase 1 trial of oral bropirimine in superficial bladder cancer. (1992) (43)
Current perspectives on diagnosis and treatment of superficial bladder cancer. (1992) (42)
Clinical Practice Recommendations for the Management of Non–Muscle Invasive Bladder Cancer (2008) (42)
Prospective randomized comparison of intravesical with percutaneous bacillus Calmette-Guerin versus intravesical bacillus Calmette-Guerin in superficial bladder cancer. (1991) (41)
Quinolone antibiotics: a potential adjunct to intravesical chemotherapy for bladder cancer. (1999) (41)
Therapy of superficial bladder cancer. (1994) (41)
Intravesical therapy for bladder cancer. (2000) (39)
Oral bropirimine immunotherapy of carcinoma in situ of the bladder: results of a phase II trial. (1996) (38)
Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma (2017) (38)
Optimal BCG treatment of superficial bladder cancer as defined by American trials. (1992) (38)
Bacillus Calmette-Guerin immunotherapy. (1987) (37)
Diagnosis and treatment of bladder cancer (1992) (36)
Cytoplasmic and nuclear androgen receptor content of normal and neoplastic human prostates and lymph node metastases of human prostatic adenocarcinoma. (1980) (35)
The use of ex vivo-activated memory T cells (autolymphocyte therapy) in the treatment of metastatic renal cell carcinoma: final results from a randomized, controlled, multisite study. (1993) (34)
Local Toxicity Patterns Associated with lntravesical bacillus Calmette‐Guérin: A Southwest Oncology Group Study (1996) (33)
A phase 2 study of TMX-101, intravesical imiquimod, for the treatment of carcinoma in situ bladder cancer. (2017) (33)
Adriamycin versus BCG in superficial bladder cancer: a Southwest Oncology Group Study. (1989) (32)
Long term protection in bladder cancer following intralesional immunotherapy. (1984) (32)
Intravesical therapy: does it affect the natural history of superficial bladder cancer? (1992) (32)
A diagnostic-prognostic test for bladder cancer using a monoclonal antibody-based enzyme-linked immunoassay for detection of urinary fibrin(ogen) degradation products. (1984) (32)
Smoking and bladder cancer. (2001) (31)
Current Approaches to the Management of Non-Muscle Invasive Bladder Cancer : Comparison of Current Guidelines and Recommendations (2008) (30)
Risk‐adapted management of low‐grade bladder tumours: recommendations from the International Bladder Cancer Group (IBCG) (2020) (30)
Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer. (1995) (29)
Maintenance Bacillus Calmette-Guerin: The Standard of Care for the Prophylaxis and Management of Intermediate- and High-Risk Non-Muscle-Invasive Bladder Cancer (2010) (29)
Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma. (2017) (28)
Immunotherapy of murine bladder cancer with keyhole limpet hemocyanin (KLH). (1993) (28)
Intravesical therapy for superficial bladder cancer: slow but steady progress. (2003) (28)
Androgen receptors in biopsy specimens of prostate adenocarcinoma. Heterogeneity of distribution and relation to prognostic significance of receptor measurements for survival of advanced cancer patients (1987) (27)
Immunotherapy of murine transitional cell carcinoma of the bladder using alpha and gamma interferon in combination with other forms of immunotherapy. (1992) (27)
Bladder cancer: current optimal intravesical treatment. (2005) (26)
Treatment of renal cell carcinoma with 5-fluorouracil and alfa-interferon. (1997) (26)
Chemoprevention of bladder cancer. (2006) (26)
Drug therapy of bacillus Calmette-Guérin sepsis (2004) (24)
Risk factors in carcinoma in situ of the urinary bladder. Commentary (1995) (24)
The preparation, handling and use of intravesical bacillus Calmette-Guerin for the management of stage Ta, T1, carcinoma in situ and transitional cell cancer. (1990) (22)
Immunotherapy for bladder cancer (2001) (20)
Adverse reactions to the intravesical administration of doxorubicin hydrochloride: report of 6 cases. (1986) (20)
LBA27 PHASE 3 STUDY OF VICINIUM IN BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER: INITIAL RESULTS (2018) (20)
A randomized prospective comparison of oral versus intravesical and percutaneous bacillus Calmette-Guerin for superficial bladder cancer. (1990) (19)
Visualization of minute centers of viral infection in unfixed cell cultures by an enzyme-linked antibody assay. (1981) (18)
Bladder cancer: Twenty years of progress and the challenges that remain (1998) (18)
Re: bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1 AND TIS) (2000) (17)
BCG immunotherapy for superficial bladder cancer (1987) (17)
Comparison of BCG with other intravesical agents. (1991) (16)
A practical guide to the use of intravesical BCG for the management of stage Ta, T1, CIS, transitional cell cancer. (1989) (15)
Management of patients with Bacilli Calmette-Guérin-refractory carcinoma in situ of the urinary bladder: cost implications of a clinical trial for valrubicin. (2000) (15)
Bropirimine immunotherapy of upper urinary tract carcinoma in situ. (1996) (14)
A BCG success story: From prevention of tuberculosis to optimal bladder cancer treatment. (2021) (13)
Inability of cytoplasmic or nuclear androgen receptor content or distribution to distinguish benign from carcinomatous human prostate. (1983) (13)
International Bladder Cancer Group Consensus Statement on Clinical Trial Design for Patients with Bacillus Calmette-Guérin-exposed High-risk Non-muscle-invasive Bladder Cancer. (2021) (13)
Long-term effect of intravesical bacillus Calmette-Guérin (BCG) Tice strain on flat carcinoma in situ of the bladder. (1989) (13)
Improving Patient Outcomes: Optimal BCG Treatment Regimen to Prevent Progression in Superficial Bladder Cancer (2006) (12)
Keyhole limpet hemocyanin immunotherapy of murine bladder cancer (2004) (12)
Contemporary oncologic outcomes of second induction course BCG in patients with nonmuscle invasive bladder cancer. (2019) (12)
Bacillus Calmette-Guérin and dinitrochlorobenzene immunotherapy of chemically induced bladder tumors. (1977) (12)
Treatment of murine transitional cell carcinoma with intralesional interleukin 2 and murine interferon gamma. (1991) (12)
Leukocyte migration inhibition in vitro in bladder carcinoma. (1979) (11)
Malignant fibrous histiocytoma of the spermatic cord. (1980) (11)
Immunochemotherapy of Bladder Carcinoma with Glucan and Cyclophosphamide (1987) (10)
Preventing warm ischemia with a polyurethane bag during renal transplantation. (1997) (10)
Pelvic recurrence after radical cystectomy: a call to arms (2015) (10)
Intravesical sequential gemcitabine and docetaxel versus bacillus calmette-guerin (BCG) plus interferon in patients with recurrent non-muscle invasive bladder cancer following a single induction course of BCG. (2021) (9)
Bladder cancer: improving care with better classification and risk stratification. (2007) (9)
IMPORTANCE OF ALPHA-FETOPROTEIN IN PATIENTS WITH SEMINOMA (1977) (9)
Current trends in bladder cancer treatment. (2000) (8)
Immunotherapy of murine bladder cancer by irradiated tumor vaccine. (1991) (8)
Tumor implantation: a rare but potentially preventable cause of death in cystectomy patients. (2010) (8)
Human prostate androgen receptor quantitation: effects of temperature on assay parameters. (1982) (8)
Androgen priming and cytotoxic chemotherapy in advanced prostatic cancer (2004) (8)
MP43-02 CG0070, AN ONCOLYTIC ADENOVIRUS, FOR BCG-UNRESPONSIVE NON-MUSCLE-INVASIVE BLADDER CANCER (NMIBC): 18 MONTH FOLLOW-UP FROM A MULTICENTER PHASE II TRIAL (2019) (8)
BCG Therapy for Superficial Bladder Cancer (1984) (8)
Diet and nutrition in urologic cancer. (2000) (8)
MULTICENTER RANDOMIZED COMPARISON OF BCG WITH OR WITHOUT ALFA 2b INTERFERON (IFN) AND ONCOVITE (ONC) VERSUS RECOMMENDED DAILY ALLOWANCE (RDA) VITAMINS DURING INDUCTION AND EXTENDED 3-WEEK MAINTENANCE (2008) (8)
EDITORIAL: THE CHALLENGE OF IMPROVED DIAGNOSTIC AND PROGNOSTIC INDICATORS OF SUPERFICIAL BLADDER CANCER (2000) (7)
MP13-19 A PHASE II/III TRIAL OF CG0070, AN ONCOLYTIC ADENOVIRUS, FOR BCG-REFRACTORY NON-MUSCLE-INVASIVE BLADDER CANCER (NMIBC) (2016) (7)
Prophylaxis for recurrent transitional cell carcinoma. (1991) (7)
A phase 3, single-arm study of CG0070 in subjects with nonmuscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG). (2022) (7)
Serum and bone marrow radioimmunoassay of acid phosphatase in prostatic cancer. (1982) (7)
The place of intravesical chemotherapy as defined by results of prospective randomized studies (substances and treatment schemes). (1992) (7)
Levamisole immunotherapy of experimental transitional cell carcinoma. (1979) (7)
MAINTENANCE BCG IMMUNOTHERAPY: EVIDENCE OF ADDITIONAL PROTECTION AGAINST CANCER (1999) (7)
Bacillus Calmette-Guerin immunotherapy of the cancer-contaminated wound. (1979) (6)
Keyhole-limpet haemacyanin and immune ribonucleic acid immunotherapy of murine transitional cell carcinoma (2004) (6)
Re: Behfar Ehdaie, Richard Sylvester, Harry W. Herr. Maintenance bacillus Calmette-Guérin treatment of non-muscle-invasive bladder cancer: a critical evaluation of the evidence. Eur Urol 2013;64:579-85. (2014) (6)
PHASE 1 STUDY OF MULTI-DOSE ADMINISTRATION OF INTRAVESICAL CG0070 IN PATIENTS WITH NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) (2008) (6)
Metallothionein isoform gene expression in four human bladder cancer cell lines (1999) (6)
Southwest Oncology Group Comparison of Bacillus Calmette-Guerin and Doxorubricin in the Treatment and Prophylaxis of Superficial Bladder Cancer (1987) (6)
IMPACT OF SMOKING ON OUTCOMES AFTER INTRAVESICAL BACILLUS CALMETTE–GUÉRIN THERAPY FOR UROTHELIAL CARCINOMA NOT INVADING MUSCLE OF THE BLADDER (2011) (5)
Deoxyribonucleic acid flow cytometry of squamous cell carcinoma of the penis. (1996) (5)
Automatic spring-loaded biopsy gun with ultrasonic control for renal transplant biopsy. (1993) (5)
Advances in the treatment of superficial bladder cancer: optimizing BCG immunotherapy. Introduction. (1995) (5)
Molecular Characterization of Bladder Cancer in Smokers versus Nonsmokers. (2016) (5)
Clinical trials of the Northgate SD-3 dual-purpose lithotriptor for renal calculi. (1992) (5)
BCG Immunotherapy of Superficial Bladder Cancer ; Treatment Results, Benefits and Risks (1991) (5)
Percutaneous, oral, or intravesical BCG administration: what is the optimal route? (1989) (5)
MP54-03 CORE1: PHASE 2, SINGLE ARM STUDY OF CG0070 COMBINED WITH PEMBROLIZUMAB IN PATIENTS WITH NON MUSCLE INVASIVE BLADDER CANCER (NMIBC) UNRESPONSIVE TO BACILLUS CALMETTE-GUERIN (BCG) (2021) (5)
844: A Phase 1 Dose-Escalation Trial of Intravesical CG0070 for Superficial Transitional Cell Carcinoma (TCC) of the Bladder after Bacillus Calmette-Guerin (BCG) Failure (2006) (5)
Cytoplasmic and nuclear androgen receptors of human prostate. (1979) (4)
Sequential immunocytological evaluation of murine transitional cell carcinoma during intralesional bacillus Calmette-Guerin and interleukin-2 immunotherapy. (1992) (4)
1785 CLINICAL EXPERIENCE WITH HEAT-INACTIVATED BACILLUS CALMETTE-GUERIN (BCG) IMMUNOTHERAPY (2013) (4)
LBA24 CG0070, AN ONCOLYTIC ADENOVIRUS, FOR BCG-UNRESPONSIVE NON-MUSCLE-INVASIVE BLADDER CANCER (NMIBC): 12 MONTH INTERIM RESULTS FROM A MULTICENTER PHASE II TRIAL (2018) (4)
Re: Assessment of conservative management for stage T10N0M0 transitional cell carcinoma of the bladder. (1997) (4)
Re: Per-Uno Malmström, Richard J. Sylvester, David E. Crawford, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol 2009;56:247-56. (2010) (4)
Erratum: Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma [Journal for Immunotherapy of Cancer., 5 (2017)(68)] DOI: 10.1186/s40425-017-0271-0 (2017) (4)
BCG in carcinoma in situ and superficial bladder tumors. (1988) (3)
Getting the Most Out of bacillus Calmette-Guérin for Treatment of Bladder Cancer. (2016) (3)
PD13-08 CORE1: PHASE 2 SINGLE ARM STUDY OF CG0070 COMBINED WITH PEMBROLIZUMAB IN PATIENTS WITH NON MUSCLE INVASIVE BLADDER CANCER UNRESPONSIVE TO BACILLUS CALMETTE-GUERIN (BCG) (2023) (3)
Perioperative management in undiagnosed pheochromocytoma. (1983) (3)
HLA-A, B and DR in Caucasians with transitional cell carcinoma of the bladder. (2008) (3)
Management of bladder cancer. (2004) (3)
Diagnosis of Non-Muscle Invasive Bladder Cancer (2008) (3)
Innovation in Bladder Cancer Immunotherapy (2016) (3)
Immunological assessment of renal cancer patients as evaluated by the lymphocyte adherence inhibition test. (1986) (3)
Cancer statistics (1990) (3)
The challenge of improved diagnostic and prognostic indicators of superficial bladder cancer. (2000) (3)
Serum lymphocyte adherence inhibition test in bladder cancer patients. (1986) (3)
Mayo Clinic Scottsdale Experience With Laparoscopic Nephroureterectomy (2004) (3)
Open questions on mechanisms (1992) (2)
Phase 1/2 Trial Results of a Large Surface Area Microparticle Docetaxel for the Treatment of High-Risk Nonmuscle-Invasive Bladder Cancer (2022) (2)
52. A Phase 1 Dose-Escalation Trial of Intravesical CG0070 for Superficial Transitional Cell Carcinoma (TCC) of the Bladder after Bacillus Calmette-Guerin (BCG) Failure (2006) (2)
INTERIM RESULTS FROM A SINGLE‐ARM MULTICENTER PHASE II TRIAL OF CG0070, AN ONCOLYTIC ADENOVIRUS, FOR BCG‐UNRESPONSIVE NON‐MUSCLE‐INVASIVE BLADDER CANCER (NMIBC): PNFLBA‐13 (2017) (2)
Optimal treatment for carcinoma in situ (1991) (2)
Advances in the treatment of superficial bladder cancer : optimizing BCG immunotherapy : proceedings of a symposium held at the 23rd World Congress of the Société Internationale d'Urologie, Sydney, Australia, September 18, 1994 (1995) (2)
A Phase 1 Trial of Durvalumab in Combination with Bacillus Calmette-Guerin (BCG) or External Beam Radiation Therapy in Patients with BCG-unresponsive Non-muscle-Invasive Bladder Cancer: The Hoosier Cancer Research Network GU16-243 ADAPT-BLADDER Study. (2023) (2)
Updated results of a phase I/II trial of intravesical CG0070 in patients with superficial bladder cancer after BCG failure. (2012) (2)
Application of the mixed cell agglutination test for cell surface antigens to renal cell carcinoma. (1982) (2)
1304: Laparoscopic Partial Nephrectomy without Hilar Clamping: The Mayo Clinic Scottsdale Experience (2004) (2)
Chemoimmunotherapy of murine bladder cancer. (1981) (1)
Recent Advances on the Nutritional Effects Associated with the Use of Garlic as a Supplement Enhanced Immunocompetence by Garlic : Role in Bladder Cancer and Other Malignancies 1 (2001) (1)
Bacillus Calmette–Guérin Immunotherapy of Genitourinary Cancer (2007) (1)
Tumor-specific immunotherapy of murine bladder cancer with butanol-extracted antigens and ethylchlorformate polymerized tumor protein. (1988) (1)
SUICIDE GENE THERAPY FOR BLADDER CANCER USING RETROVIRUS MEDIATED DELIVERY IN A MURINE MODEL (1999) (1)
Updated results of a phase I/II trial of intravesical CG0070 in patients with superficial bladder cancer after BCG failure. (2012) (1)
Intravesical Therapy – BCG and Beyond (2019) (1)
Advances in the Treatment of Superficial Bladder Cancer: Optimizing BCG Immunotherapy: Symposium held at the 23rd World Congress of the Société Internationale d' Urologie, Sydney, Septemer 1994: Proceedings (1995) (1)
Molecular characterization of bladder cancer in smokers versus non-smokers. (2015) (1)
[A comparative clinical trial of intravesical BCG and adriamycin treatment in superficial bladder cancer. A South West Oncology Group Study]. (1986) (1)
Intravesical immunotherapy: BCG (2008) (1)
Clinical role of the mixed cell agglutination test in the prospective management of superficial bladder tumors (1980) (1)
Campbell's Urology: Review and Assessment (1995) (1)
Intravesical bacillus Calmette-Guérin and second primary malignancies. (1989) (1)
Sequential whole bladder photodynamic therapy (WBPT) in the management of recurrent superficial bladder cancer (2001) (1)
Bladder cancer: improving patient selection and treatment. (1995) (1)
533 CURRENT PRACTICE GAPS IN THE USE OF BCG MAINTENANCE: RESULTS OF THE INTERNATIONAL PATIENT DATA SURVEY (2012) (1)
Erratum to: Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma (2017) (1)
Optimal treatment of superficial bladder cancer in 1994. (1995) (1)
Is a second transurethral resection necessary in T1 bladder cancer? (2007) (1)
LBA02-02 INITIAL RESULTS FROM A PHASE 1/2 TRIAL OF LARGE SURFACE AREA MICROPARTICLE DOCETAXEL FOR HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER (2021) (1)
Cisplatin, gemcitabine and paclitaxel triplet chemotherapy in 50 patients with advanced or metastatic urothelial cancer. (2006) (1)
THE EFFECT OF TREADMILL EXERCISE ON THE DEVELOPMENT OF PROSTATE CANCER IN RATS 1195 (1997) (1)
Review Article CHEMOPREVENTION OF UROLOGICAL CANCER (1999) (0)
2160 Strontium-89 and maximum androgen blockade: Reducing tumor burden in the bone in metastatic prostate cancer (1999) (0)
Campbell's urology (2013) (0)
Salvage Hyperthermic Gemcitabine and Docetaxel Combination Chemotherapy After BCG Failure in Non-Muscle Invasive Bladder Cancer Patients (2020) (0)
Integrative Tumor Board: Medical and Surgical Oncology Approach (2005) (0)
A case report of multimodality therapy of bladder cancer. (1994) (0)
Immunotheapy and immunodiagnostic studies in carcinoma of the bladder (1986) (0)
The role of BCG in the treatment of superficial bladder cancer. (1999) (0)
EDITORIAL: MANAGEMENT OF BLADDER CANCER (2004) (0)
Editorial Comment. (2018) (0)
MP08-05 PHASE 1a/b STUDY OF INTRAVESICAL INSTILLATION OF TARA-002 IN ADULTS WITH HIGH-GRADE NON-MUSCLE INVASIVE BLADDER CANCER (2023) (0)
A Trial of Bacillus Calmette-Guérin Versus Adriamycin in Superficial Bladder Cancer: A South-West Oncology Group Study (1987) (0)
MP63-01 AN INTERIM ANALYSIS OF A PHASE II CLINICAL STUDY OF INTRAVESICAL PHOTO DYNAMIC THERAPY IN PATIENTS WITH BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) CARCINOMA IN-SITU (CIS) (2023) (0)
Comment on: A Randomized Trial of Radical Radiotherapy for the Management of pTlG3 NXMO Transitional Cell Carcinoma of the Bladder. Authors' reply (2008) (0)
9. BeG immunotherapy for superficial bladder cancer (1987) (0)
RE: Editorial: bladder cancer. (1994) (0)
COMMENT ON: ASSESSMENT OF CONSERVATIVE MANAGEMENT FOR STAGE T10N0M0 TRANSITIONAL CELL CARCINOMA OF THE BLADDER. AUTHORS' REPLY (1997) (0)
Re: Transitional Cell Carcinoma of the Prostate, by H. Matzkin, M. S. Soloway and S. Hardeman, J. Urol., 146: 1207–1212, 1991 (1992) (0)
Predicting response to bacillus Calmette-Guérin: time to look beyond the ages. (2014) (0)
Palliative Effect of Intravesical Bacillus Calmette-Guerin in Elderly Patients With Advanced Bladder Carcinoma: Editorial Comment (1997) (0)
EFFECTS OF EXERCISE WITH AND WITHOUT BCG ON PROSTATE CANCER IN RATS (1998) (0)
CHAPTER 26 – Bladder Cancer (2006) (0)
Mixed cell agglutination test: correlation with invasive potential of superficial transitional cell carcinoma. (1978) (0)
Re: Transitional cell carcinoma of the prostate. (1992) (0)
Re: Richard J. Sylvester, Willem Oosterlinck, Sten Holmang, et al. Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa-pT (2015) (0)
Smoking and renal cell carcinoma. (2001) (0)
Safety of sequential whole bladder photodynamic therapy (WBPT) in bladder cancer (2001) (0)
Re: Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer s. P. Lerner, C. M. Tangen, H. Sucharew, D. Wood and E. D. Crawford J Urol 2007; 177: 1727-1731. (2008) (0)
Multi-Institution Evaluation of Sequential Intravesical Gemcitabine and Docetaxel in the Treatment of Bacillus Calmette-Guerin Naïve Patients with Non-Muscle Invasive Bladder Cancer (2022) (0)
TRANSITIONAL CELL CARCINOMA OF THE PROSTATE. AUTHOR REPLY (1992) (0)
Reduced Dose Intravesical Bacillus Calmette-Guérin: Why It Might Not Matter (2022) (0)
Oncolytic and Immunotherapeutic CG0070 Adenovirus for High-risk Bacillus Calmette-Guerin Unresponsive Bladder Cancer (2021) (0)
Re: Editorial: Bladder Cancer by M. J. Droller J. Urol., 151: 47-48, 1994 (1994) (0)
Rapid screening of potential human bladder carcinogens: genotoxicity in meiosis repair deficient Drosophila melanogaster. (1989) (0)
PD03-07 A MULTI-INSTITUTIONAL EVALUATION OF RESCUE THERAPY WITH INTRAVESICAL GEMCITABINE AND DOCETAXOL FOR NON-MUSCLE INVASIVE BLADDER CANCER AFTER BCG FAILURE (2020) (0)
Immunotherapy of Superficial Bladder Cancer (1994) (0)
LB-S&T-21 A PHASE 2 STUDY OF VESIMUNE®, INTRAVESICAL IMIQUIMOD, FOR THE TREATMENT OF CARCINOMA IN SITU BLADDER CANCER (2016) (0)
Words of wisdom. Re: Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial c (2011) (0)
Patient selection : panel disccusion 1 (1992) (0)
Clinical Scenario: Management of Side Effects from Bacillus Calmette-Guérin Bladder Instillation (2015) (0)
Abstract CT233: A phase 3, single-arm study of CG0070 in subjects with non-muscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG) (2022) (0)
BCG - A New Standard for Superficial Bladder Cancer: Symposium held at the 22nd Congress of the Société Internationale d'Urologie, Seville, Spain, November 1991: Proceedings (1992) (0)
Clinical evaluation of immunotherapy: are there differences between papillary and flat in situ bladder cancer? (1998) (0)
Guest Editorʼs introduction (1992) (0)
Editorial Comment: A 12 Versus 6-Week Course of Bacillus Calmette-Guerin Prophylaxis for the Treatment of High Risk Superficial Bladder Cancer (1997) (0)
Leukocyte Migration Inhibition in Vitro in Bladder Carcinoma 1 (2006) (0)
Carcinoma of the bladder. (1985) (0)
Editorial comment. (2011) (0)
A phase II clinical study of intravesical photo dynamic therapy in patients with BCG-unresponsive NMIBC (interim analysis). (2023) (0)
Safety of two sequential whole bladder photodynamic therapy (WBPDT) treatments in the management of resistant bladder cancer (2003) (0)
LYMPHOCYTE RESPONSE TO RUNNING WHEEL EXERCISE TRAINING IN RATS WITH PROSTATE CANCER (1999) (0)
Using alpha-interferon as an adjunctive therapy to reduce the dose of energy required with photodynamic therapy in treating human bladder tumors: cell culture results (2001) (0)
CYTOTOXIC EFFECT OF NERIUM OLEANDER EXTRACT (ANVIRZEL [TM]) ON BLADDER CANCER CELLS (1999) (0)
7. Intravesical immunotherapy (2015) (0)
426 A phase 3, single-arm study of CG0070 in subjects with non-muscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG) (2021) (0)
Activity of intravesical CG0070 in Rb-inactive superficial bladder cancer after BCG failure: Updated results of a phase I/II trial. (2012) (0)
Re: Editorial Comments (2008) (0)
Bacillus Calmette‐Guerin Immunotherapy Significantly Prolongs Survival of Animals with Prostate Cancer (1999) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Dr Donald L. Lamm?

Dr Donald L. Lamm is affiliated with the following schools: